American Journal of Cardiovascular Drugs

, Volume 12, Issue 4, pp 263–277 | Cite as

Tolerability of Angiotensin-Receptor Blockers in Patients with Intolerance to Angiotensin-Converting Enzyme Inhibitors

A Systematic Review and Meta-Analysis
  • Daniel Caldeira
  • Cláudio David
  • Cristina Sampaio
Systematic Review

Abstract

Background

Between 5% and 20% of patients treated with angiotensin-converting enzyme inhibitors (ACE inhibitors) develop intolerance. Angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) can be used as an alternative treatment.

Objective

In this study we aimed to evaluate the tolerability of ARBs in patients with intolerance to ACE inhibitors.

Data Sources

The electronic databases PubMed, MEDLINE/EMBASE via Dialog, CENTRAL, and ISI Web of Knowledge were searched.

Study Selection

Randomized controlled trials (RCTs) evaluating ARBs in patients with intolerance to ACE inhibitors were selected.

Data Synthesis

Risk ratio (RR) and 95% confidence intervals (CIs) were estimated assuming the random effects method. We found 11 RCTs comparing ARBs with ACE inhibitors, diuretics, or placebo, and one RCT comparing high-dose versus low-dose ARB.

Results

ARBs had fewer cough events versus ACE inhibitors (RR 0.37; 95% CI 0.28, 0.48). ARBs had drug discontinuation (RR 0.99; 95% CI 0.84, 1.17) and cough risk (RR 1.01; 95% CI 0.74, 1.39) rates similar to placebo. Angioedema risk with ARBs was also similar to placebo (RR 1.62; 95% CI 0.17, 15.79). Compared with placebo, hypotension (RR 2.63; 95% CI 1.77, 3.92), renal dysfunction (RR 2.07; 95% CI 1.45, 2.95) and hyperkalemia (RR 3.37; 95% CI 1.60, 7.11) were more frequent with ARBs.

Conclusions

ACE inhibitor rechallenge should be discouraged in patients with previous intolerance to ACE inhibitors due to a higher risk of cough. ARBs had cough and angioedema incidences similar to placebo. Despite a significantly higher incidence of hypotension, renal dysfunction and hyperkalemia, discontinuation of ARBs was similar to placebo.

References

  1. 1.
    Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007; 13: 9–20PubMedGoogle Scholar
  2. 2.
    Pitt B. RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice. Heart 2009; 95: 1205–8PubMedCrossRefGoogle Scholar
  3. 3.
    Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369: 1208–19PubMedCrossRefGoogle Scholar
  4. 4.
    Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234–42PubMedCrossRefGoogle Scholar
  5. 5.
    Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians’ Desk Reference. Am J Med 2010; 123: 1016–30PubMedCrossRefGoogle Scholar
  6. 6.
    Morimoto T, Gandhi TK, Fiskio JM, et al. Development and validation of a clinical prediction rule for angiotensin-converting enzyme inhibitor-induced cough. J Gen Intern Med 2004; 19: 684–91PubMedCrossRefGoogle Scholar
  7. 7.
    Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004; 10: 499–509PubMedCrossRefGoogle Scholar
  8. 8.
    Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391–479PubMedCrossRefGoogle Scholar
  9. 9.
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906PubMedCrossRefGoogle Scholar
  10. 10.
    Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752–60Google Scholar
  11. 11.
    ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59PubMedCrossRefGoogle Scholar
  12. 12.
    Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–6PubMedCrossRefGoogle Scholar
  13. 13.
    Yusuf S, Pfeffer MA, Swedberg K, et al., CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777–81PubMedCrossRefGoogle Scholar
  14. 14.
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1–12PubMedCrossRefGoogle Scholar
  15. 15.
    Lacourcière Y, Brunner H, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group. J Hypertens 1994; 12: 1387–93Google Scholar
  16. 16.
    Ramsay LE, Yeo WW. ACE inhibitors, angiotensin II antagonists and cough. The Losartan Cough Study Group. J Hum Hypertens 1995; 9 Suppl. 5: S51–4PubMedGoogle Scholar
  17. 17.
    Ramsay LE, Yeo WW, Losartan Cough Study Group. Double-blind comparison of losartan, lisinopril and hydrochlorothiazide in hypertensive patients with a previous angiotensin converting enzyme inhibitor-associated cough. J Hypertens Suppl 1995; 13: S73–6PubMedCrossRefGoogle Scholar
  18. 18.
    Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997; 37: 101–7PubMedCrossRefGoogle Scholar
  19. 19.
    Chan P, Tomlinson B, Huang TY, et al. Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. J Clin Pharmacol 1997; 37: 253–7PubMedCrossRefGoogle Scholar
  20. 20.
    Paster RZ, Snavely DB, Sweet AR, et al. Use of losartan in the treatment of hypertensive patients with a history of cough induced by angiotensin-converting enzyme inhibitors. Clin Ther 1998; 20: 978–89PubMedCrossRefGoogle Scholar
  21. 21.
    Lacourciére Y. The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Telmisartan Cough Study Group. Int J Clin Pract 1999; 53: 99–103Google Scholar
  22. 22.
    Tanser PH, Campbell LM, Carranza J, et al. Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Multicentre Cough Study Group. Am J Hypertens 2000; 13: 214–8CrossRefGoogle Scholar
  23. 23.
    Rake EC, Breeze E, Fletcher AE. Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo. J Hum Hypertens 2001; 15: 863–7PubMedCrossRefGoogle Scholar
  24. 24.
    Maggioni AP, Anand I, Gottlieb SO, et al., Val-HeFT Investigators (Valsartan Heart Failure Trial). Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002; 40: 1414–21PubMedCrossRefGoogle Scholar
  25. 25.
    Granger CB, Ertl G, Kuch J, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J 2000; 139: 609–17PubMedCrossRefGoogle Scholar
  26. 26.
    Telmisartan Randomised Assessment Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174–83PubMedCrossRefGoogle Scholar
  27. 27.
    Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374: 1840–8PubMedCrossRefGoogle Scholar
  28. 28.
    Bradburn MJ, Deeks JJ, Berlin JA, et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007; 26: 53–77PubMedCrossRefGoogle Scholar
  29. 29.
    Heran BS, Wong MM, Heran IK, et al. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev 2008; CD003822Google Scholar
  30. 30.
    Charlon V, Dollow S, Fidel J, et al. Reproducibility of angiotensin converting enzyme inhibitor induced cough: a double-blind randomised study. Br J Clin Pharmacol 1995; 39: 125–9PubMedCrossRefGoogle Scholar
  31. 31.
    Tomiyama H, Motobe K, Zaydun G, et al. Insulin sensitivity and endothelial function in hypertension: a comparison of temocapril and candesartan. Am J Hypertens 2005; 18: 178–82PubMedCrossRefGoogle Scholar
  32. 32.
    Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation 2005; 111: 315–20PubMedCrossRefGoogle Scholar
  33. 33.
    Grilo A, Sáez-Rosas MP, Santos-Morano J, et al. Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough. Pharmacogenet Genomics 2011; 21: 10–7PubMedCrossRefGoogle Scholar
  34. 34.
    Mukae S, Itoh S, Aoki S, et al. Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough. J Hum Hypertens 2002; 16: 857–63PubMedCrossRefGoogle Scholar
  35. 35.
    Haymore BR, Yoon J, Mikita CP, et al. Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Ann Allergy Asthma Immunol 2008; 101: 495–9PubMedCrossRefGoogle Scholar
  36. 36.
    Bas M, Adams V, Suvorava T, et al. Nonallergic angioedema: role of bradykinin. Allergy 2007; 62: 842–56PubMedCrossRefGoogle Scholar
  37. 37.
    Bas M, Greve J, Stelter K, et al. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med 2010; 56: 278–82PubMedCrossRefGoogle Scholar
  38. 38.
    Winkelmayer WC, Zhang Z, Shahinfar S, et al. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care 2006; 29: 2210–7PubMedCrossRefGoogle Scholar
  39. 39.
    Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160: 685–93PubMedCrossRefGoogle Scholar
  40. 40.
    Matys T, Pawlak R, Kucharewicz I, et al. Hypotensive effect of angiotensin II after AT1-receptor blockade with losartan. J Physiol Pharmacol 2000; 51: 161–6PubMedGoogle Scholar
  41. 41.
    Sica DA, Gehr TW, Yancy C. Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism. Congest Heart Fail 2003; 9: 224–9PubMedCrossRefGoogle Scholar
  42. 42.
    Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 2008; 14: 181–8PubMedCrossRefGoogle Scholar
  43. 43.
    Phillips CO, Kashani A, Ko DK, et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007 1; 67: 1930–6CrossRefGoogle Scholar
  44. 44.
    Brown NJ, Ray WA, Snowden M, et al. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996; 60: 8–13PubMedCrossRefGoogle Scholar
  45. 45.
    Bas M, Hoffmann TK, Tiemann B, et al. Potential genetic risk factors in angiotensin-converting enzyme-inhibitor-induced angio-oedema. Br J Clin Pharmacol 2010; 69: 179–86PubMedCrossRefGoogle Scholar
  46. 46.
    Bender R, Bunce C, Clarke M, et al. Attention should be given to multiplicity issues in systematic reviews. J Clin Epidemiol 2008; 61: 857–65PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Daniel Caldeira
    • 1
  • Cláudio David
    • 1
    • 2
  • Cristina Sampaio
    • 1
    • 3
  1. 1.Clinical Pharmacology and Therapeutics Laboratory, Faculty of MedicineLisbonPortugal
  2. 2.Department of CardiologySanta Maria University HospitalLisbonPortugal
  3. 3.Institute of Molecular MedicineLisbonPortugal

Personalised recommendations